2019冠状病毒病哮喘患者:来自三级中心的病例研究,关于他们的表型和他们对远程医疗哮喘治疗的依从性。

IF 0.8 Q4 RESPIRATORY SYSTEM
Buket Çalışkaner Öztürk, Nejdiye Güngördü Mazıcan, Elif Buse Çalışkan, Ali Ata Tuz, Bilun Gemicioğlu
{"title":"2019冠状病毒病哮喘患者:来自三级中心的病例研究,关于他们的表型和他们对远程医疗哮喘治疗的依从性。","authors":"Buket Çalışkaner Öztürk,&nbsp;Nejdiye Güngördü Mazıcan,&nbsp;Elif Buse Çalışkan,&nbsp;Ali Ata Tuz,&nbsp;Bilun Gemicioğlu","doi":"10.5152/TurkThoracJ.2021.21097","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to determine the prevalence and the characteristics of coronavirus disease 2019 (COVID-19) in a tertiary outpatient clinic of asthma patients, find the predisposing asthma phenotype to COVID-19, and to see their adherence to asthma treatment.</p><p><strong>Material and methods: </strong>A retrospective, cross-sectional, real life study was conducted via phone interviews with the patients being followed in the asthma outpatient clinic. From the files of the patient information was obtained about their demographics, asthma phenotype, co-morbidity, prick tests, spirometry test results and their medications at the last visit before the COVID-19 pandemic. Information's about asthma exacerbations, ACT, asthma treatment adherence and history of COVID-19 were obtained via telephone interviews.</p><p><strong>Results: </strong>Of the 573 patients with asthma, 13 (2.26%) had COVID-19 history. The mean age of patients with asthma and COVID-19 was 51.84±14.92 year. Two patients were on mepolizumab and one was on omalizumab treatment. Mean ACT was 19.84±2.73. Lack of adherence was reported in 8% of all patients with asthma compared to 23% in the patients who had COVID-19. Asthma exacerbation was seen during the course of SARS-CoV2 infection in 3 of 13 patients with asthma. Asthma exacerbations were reported during the period of one month following COVID-19 in 2 patients.</p><p><strong>Conclusion: </strong>The most common asthma phenotype in the cases of COVID-19 was obese phenotype. Rates of using biological agents and non-adherence to the treatment were found to be higher. Asthma exacerbation may be seen during course of COVID-19 albeit being less common.</p>","PeriodicalId":37452,"journal":{"name":"Turkish Thoracic Journal","volume":"23 1","pages":"25-31"},"PeriodicalIF":0.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/00/ttj-23-1-25.PMC9450126.pdf","citationCount":"0","resultStr":"{\"title\":\"Coronavirus Disease 2019 in Patients with Asthma: Case Study from a Tertiary Center Regarding Their Phenotypes and Their Adherence to Asthma Treatment by Telemedicine.\",\"authors\":\"Buket Çalışkaner Öztürk,&nbsp;Nejdiye Güngördü Mazıcan,&nbsp;Elif Buse Çalışkan,&nbsp;Ali Ata Tuz,&nbsp;Bilun Gemicioğlu\",\"doi\":\"10.5152/TurkThoracJ.2021.21097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The aim of this study was to determine the prevalence and the characteristics of coronavirus disease 2019 (COVID-19) in a tertiary outpatient clinic of asthma patients, find the predisposing asthma phenotype to COVID-19, and to see their adherence to asthma treatment.</p><p><strong>Material and methods: </strong>A retrospective, cross-sectional, real life study was conducted via phone interviews with the patients being followed in the asthma outpatient clinic. From the files of the patient information was obtained about their demographics, asthma phenotype, co-morbidity, prick tests, spirometry test results and their medications at the last visit before the COVID-19 pandemic. Information's about asthma exacerbations, ACT, asthma treatment adherence and history of COVID-19 were obtained via telephone interviews.</p><p><strong>Results: </strong>Of the 573 patients with asthma, 13 (2.26%) had COVID-19 history. The mean age of patients with asthma and COVID-19 was 51.84±14.92 year. Two patients were on mepolizumab and one was on omalizumab treatment. Mean ACT was 19.84±2.73. Lack of adherence was reported in 8% of all patients with asthma compared to 23% in the patients who had COVID-19. Asthma exacerbation was seen during the course of SARS-CoV2 infection in 3 of 13 patients with asthma. Asthma exacerbations were reported during the period of one month following COVID-19 in 2 patients.</p><p><strong>Conclusion: </strong>The most common asthma phenotype in the cases of COVID-19 was obese phenotype. Rates of using biological agents and non-adherence to the treatment were found to be higher. Asthma exacerbation may be seen during course of COVID-19 albeit being less common.</p>\",\"PeriodicalId\":37452,\"journal\":{\"name\":\"Turkish Thoracic Journal\",\"volume\":\"23 1\",\"pages\":\"25-31\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/00/ttj-23-1-25.PMC9450126.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turkish Thoracic Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5152/TurkThoracJ.2021.21097\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Thoracic Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/TurkThoracJ.2021.21097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

摘要

目的:了解某三级门诊哮喘患者2019冠状病毒病(COVID-19)的患病率及特征,发现易患COVID-19的哮喘表型,并观察其对哮喘治疗的依从性。材料和方法:通过电话访谈对哮喘门诊患者进行回顾性、横断面、真实生活研究。从患者档案中获取患者在COVID-19大流行前最后一次就诊时的人口统计学信息、哮喘表型、合并症、点刺试验、肺活量测定结果和用药信息。通过电话访问获得哮喘加重、ACT、哮喘治疗依从性和COVID-19病史等信息。结果:573例哮喘患者中有新冠肺炎病史13例(2.26%)。哮喘合并新冠肺炎患者的平均年龄为51.84±14.92岁。两名患者接受美波珠单抗治疗,一名接受奥玛珠单抗治疗。平均ACT为19.84±2.73。在所有哮喘患者中,有8%的人缺乏依从性,而在COVID-19患者中,这一比例为23%。13例哮喘患者中有3例在SARS-CoV2感染过程中出现哮喘加重。2例患者在COVID-19感染后1个月内出现哮喘加重。结论:新冠肺炎患者中最常见的哮喘表型为肥胖表型。使用生物制剂和不坚持治疗的比率较高。在COVID-19期间可能会出现哮喘恶化,尽管不太常见。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Coronavirus Disease 2019 in Patients with Asthma: Case Study from a Tertiary Center Regarding Their Phenotypes and Their Adherence to Asthma Treatment by Telemedicine.

Coronavirus Disease 2019 in Patients with Asthma: Case Study from a Tertiary Center Regarding Their Phenotypes and Their Adherence to Asthma Treatment by Telemedicine.

Objective: The aim of this study was to determine the prevalence and the characteristics of coronavirus disease 2019 (COVID-19) in a tertiary outpatient clinic of asthma patients, find the predisposing asthma phenotype to COVID-19, and to see their adherence to asthma treatment.

Material and methods: A retrospective, cross-sectional, real life study was conducted via phone interviews with the patients being followed in the asthma outpatient clinic. From the files of the patient information was obtained about their demographics, asthma phenotype, co-morbidity, prick tests, spirometry test results and their medications at the last visit before the COVID-19 pandemic. Information's about asthma exacerbations, ACT, asthma treatment adherence and history of COVID-19 were obtained via telephone interviews.

Results: Of the 573 patients with asthma, 13 (2.26%) had COVID-19 history. The mean age of patients with asthma and COVID-19 was 51.84±14.92 year. Two patients were on mepolizumab and one was on omalizumab treatment. Mean ACT was 19.84±2.73. Lack of adherence was reported in 8% of all patients with asthma compared to 23% in the patients who had COVID-19. Asthma exacerbation was seen during the course of SARS-CoV2 infection in 3 of 13 patients with asthma. Asthma exacerbations were reported during the period of one month following COVID-19 in 2 patients.

Conclusion: The most common asthma phenotype in the cases of COVID-19 was obese phenotype. Rates of using biological agents and non-adherence to the treatment were found to be higher. Asthma exacerbation may be seen during course of COVID-19 albeit being less common.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Turkish Thoracic Journal
Turkish Thoracic Journal Medicine-Pulmonary and Respiratory Medicine
CiteScore
1.40
自引率
11.10%
发文量
2
期刊介绍: Turkish Thoracic Journal (Turk Thorac J) is the double-blind, peer-reviewed, open access, international publication organ of Turkish Thoracic Society. The journal is a quarterly publication, published on January, April, July, and October and its publication language is English. Turkish Thoracic Journal started its publication life following the merger of two journals which were published under the titles “Turkish Respiratory Journal” and “Toraks Journal” until 2007. Archives of both journals were passed on to the Turkish Thoracic Journal. The aim of the journal is to convey scientific developments and to create a dynamic discussion platform about pulmonary diseases. With this intent, the journal accepts articles from all related scientific areas that address adult and pediatric pulmonary diseases, as well as thoracic imaging, environmental and occupational disorders, intensive care, sleep disorders and thoracic surgery. Clinical and research articles, reviews, statements of agreement or disagreement on controversial issues, national and international consensus reports, abstracts and comments of important international articles, interesting case reports, writings related to clinical and practical applications, letters to the editor, and editorials are accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信